G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 25 PLN -1.57% Market Closed
Market Cap: 33m PLN
Have any thoughts about
Genomed SA?
Write Note

Net Margin
Genomed SA

2.7%
Current
3%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2.7%
=
Net Income
588.7k
/
Revenue
22.1m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
PL
Genomed SA
WSE:GEN
33m PLN
3%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
314.9B USD
9%
US
Amgen Inc
NASDAQ:AMGN
140.6B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.9B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.8B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country PL
Market Cap 33m PLN
Net Margin
3%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 314.9B USD
Net Margin
9%
Country US
Market Cap 140.6B USD
Net Margin
13%
Country US
Market Cap 115.7B USD
Net Margin
0%
Country US
Market Cap 103.9B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 77.8B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Genomed SA
Glance View

Market Cap
33m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
25.37 PLN
Undervaluation 1%
Intrinsic Value
Price
G

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2.7%
=
Net Income
588.7k
/
Revenue
22.1m
What is the Net Margin of Genomed SA?

Based on Genomed SA's most recent financial statements, the company has Net Margin of 2.7%.